Amedisys (NASDAQ:AMED) Earns Buy Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Amedisys (NASDAQ:AMED) in a research note released on Saturday. The firm issued a buy rating on the health services provider’s stock.

Amedisys Stock Up 0.1 %

Amedisys stock opened at $92.29 on Friday. The company has a market capitalization of $3.02 billion, a P/E ratio of -297.70, a P/E/G ratio of 4.34 and a beta of 0.86. The firm’s fifty day simple moving average is $93.66 and its 200-day simple moving average is $93.61. The company has a current ratio of 1.05, a quick ratio of 1.05 and a debt-to-equity ratio of 0.32. Amedisys has a 1-year low of $71.06 and a 1-year high of $96.44.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, February 21st. The health services provider reported $0.94 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.10). The business had revenue of $570.79 million for the quarter, compared to the consensus estimate of $566.85 million. Amedisys had a negative net margin of 0.44% and a positive return on equity of 12.76%. The firm’s revenue for the quarter was up 1.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.16 EPS. Sell-side analysts forecast that Amedisys will post 4.54 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AMED. FIL Ltd acquired a new stake in Amedisys in the 4th quarter worth $124,085,000. Pentwater Capital Management LP grew its position in Amedisys by 239.5% in the 3rd quarter. Pentwater Capital Management LP now owns 1,144,000 shares of the health services provider’s stock worth $106,850,000 after purchasing an additional 807,000 shares during the last quarter. Westchester Capital Management LLC grew its position in Amedisys by 269.7% in the 3rd quarter. Westchester Capital Management LLC now owns 850,386 shares of the health services provider’s stock worth $79,426,000 after purchasing an additional 620,386 shares during the last quarter. Water Island Capital LLC boosted its position in shares of Amedisys by 185.0% during the 4th quarter. Water Island Capital LLC now owns 710,697 shares of the health services provider’s stock valued at $67,559,000 after acquiring an additional 461,368 shares in the last quarter. Finally, Mackenzie Financial Corp boosted its position in shares of Amedisys by 67.7% during the 1st quarter. Mackenzie Financial Corp now owns 956,780 shares of the health services provider’s stock valued at $164,844,000 after acquiring an additional 386,411 shares in the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.